Clin2
NCT06415318Possibly a fitRecruiting

TIP chemo plus triplizumab before surgery for penile cancer

Penile Cancer

Part of Cancer, Kidney & urinary clinical trials.

This trial tests a combination of chemotherapy drugs (paclitaxel, ifosfamide, cisplatin) and an immunotherapy drug (triplizumab) given before surgery for locally advanced penile cancer. The goal is to shrink the tumor and improve outcomes.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
25 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You must have squamous cell carcinoma of the penis confirmed by a biopsy or other test.
  • Your cancer should be locally advanced (stage T4 or N3).
  • You cannot have had chemotherapy for this cancer in the last 12 months.
  • You must have at least one tumor that can be measured on a scan (like a CT or MRI).
  • You should be in fairly good health, able to walk and take care of yourself (ECOG score 0-2).
  • Your blood counts, liver, and kidney function must be within certain ranges.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07767266Not yet recruiting· Phase 2
Pre-surgery treatment with pucotenlimab and becotatug vedotin for penile cancer

This trial tests two drugs given before surgery for penile cancer that has spread to nearby tissues or lymph nodes. The goal is to see if this combination can shrink tumors and improve outcomes. The drugs work by helping the immune system attack cancer cells and delivering chemotherapy directly to them.

Guangzhou, Guangdong
NCT06353906Recruiting· Phase 2
Chemo plus immunotherapy for advanced penile cancer

This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab (Keytruda) for penile cancer that has spread to nearby lymph nodes. The goal is to see if this combination can shrink or control the cancer before or after surgery.

Leuven
NCT07518979Recruiting· Phase 2
EGFR-targeted drug plus immunotherapy for advanced penile cancer

This trial tests a new combination treatment for advanced penile cancer that hasn't been treated before. It combines a targeted drug (becotatug vedotin) designed to attack cancer cells with an immunotherapy drug (pucotenlimab) that helps your immune system fight cancer.

Chengdu, Sichuan
NCT07497919Not yet recruiting· Phase 2
Combination therapy for EGFR-positive advanced penile cancer

This trial tests two drugs — becotatug vedotin and pucotenlimab — together in people with advanced penile cancer whose tumors show a protein called EGFR. It aims to see if this combination can shrink or slow the cancer.

NCT06684327Recruiting· Phase 2
Study of three chemotherapy drugs for rare advanced cancers

This trial tests a combination of three chemotherapy drugs (albumin-paclitaxel, ifosfamide, and cisplatin) for people with certain rare cancers that have spread to other parts of the body (stage IV). It looks at how well the treatment works and if it is safe.

Shanghai, Shanghai Municipality
NCT07101822Not yet recruiting· Phase 2
Cemiplimab vs best care after chemo for advanced penile cancer

This trial tests whether a maintenance drug called cemiplimab (an immunotherapy) can help keep your penile cancer from growing after you've finished platinum-based chemotherapy. It's a randomized study, so half the participants get cemiplimab and the other half get the best standard care, so doctors can compare which works better.

São Paulo, São Paulo

Hear when a new Penile Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.